다미아나

Evaluation of herbal dietary supplements marketed on the internet for recreational use.

1. Ann Pharmacother. 2005 Oct;39(10):1634-9. doi: 10.1345/aph.1G185. Epub 2005 Sep 13. Evaluation of herbal dietary supplements marketed on the internet for recreational use. Dennehy CE(1), Tsourounis C, Miller AE. Author information: (1)School of Pharmacy, University of California, San Francis

Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis.

2. Biol Direct. 2023 Oct 13;18(1):66. doi: 10.1186/s13062-023-00423-4. Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis. Scuteri D(1)(2), Pocobelli G(3), Sakurada Y(4), Russo R(5), Tonin P(6), Nicotera P(7), Bagetta G(8

The Impact of a Standardized Oral Multinutrient Supplementation on Embryo Quality in in vitro Fertilization/Intracytoplasmic Sperm Injection: A Prospective Randomized Trial.

1. Gynecol Obstet Invest. 2017;82(1):8-14. doi: 10.1159/000452662. Epub 2016 Nov 11. The Impact of a Standardized Oral Multinutrient Supplementation on Embryo Quality in in vitro Fertilization/Intracytoplasmic Sperm Injection: A Prospective Randomized Trial. Nouri K(1), Walch K, Weghofer A, Imhof M, Egarter C, Ott J. Author information: (1)Clinical Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Vienna, Austria. The role of micronutrients in fertility has recently gained increased attention. We aimed to test the impact of a standardized, multinutrient supplementation on outcomes after in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in a pilot study. One hundred women undergoing IVF/ICSI were prospectively included and randomized to receive either a multinutrient supplementation named PROfertil® female that included folic acid, selenium, vitamin E, catechins, glycyrrhizin, diosgenin, damiana and omega-3-fatty acids (study group; n = 50), or 400 µg folic acid (control group; n = 50). Outcome parameters were embryo quality on day 3 after oocyte retrieval (good quality vs. poor quality) and the clinical pregnancy rate. In an intention-to-treat analyses, a higher rate of women with at least one good quality embryo (with at least 6 cells and a fragmentation rate <20%) were found for the study (29/50, 58.0%) compared to the control group (18/50, 36.0%; p = 0.045 in chi-square test; relative risk 1.611, 95% CI 1.009-2.597). In conclusion, a multinutrient supplementation that includes folic acid, selenium, vitamin E, catechins, glycyrrhizin, diosgenin, damiana and omega-3-fatty acids seems beneficial in terms of embryo quality. © 2016 S. Karger AG, Basel. DOI: 10.1159/000452662 PMID: 27832646 [Indexed for MEDLINE]

The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status.

2. J Sex Marital Ther. 2006 Oct-Dec;32(5):369-78. doi: 10.1080/00926230600834901. The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. Ito TY(1), Polan ML, Whipple B, Trant AS. Author information: (1)School of Medicine, University of Hawaii, Honolulu, Hawaii, USA. We conducted a double-blind, placebo-controlled study to determine the role of dietary supplementation on sexual function in women of differing menopausal status. One hundred eight (108) women, age 22-73 years, who reported a lack of sexual desire, enrolled as participants. Of these, 55 received ArginMax for women and 53 received placebo. ArginMax for women contains L-arginine, ginseng, ginkgo, damiana, multivitamins, and minerals. The 108 women, given definitions, self-reported as 59 premenopausal (PRE); 20 perimenopausal (PERI), and 29 postmenopausal (POST). After 4 weeks, PRE women on ArginMax primarily reported significant improvement in level of sexual desire (72%; p = 0.03) and satisfaction with overall sex life (68%; p = 0.007), compared with placebo group, according to the Female Sexual Function Index (FSFI; Kaplan et al., 1999) scales. Frequency of sexual desire (60%; p = 0.05) and frequency of intercourse (56% p = 0.01) also increased among the PRE women. In contrast, among PERI women, primary improvements were reported for frequency of intercourse (86%; p = 0.002), satisfaction with sexual relationship (79%; p = 0.03), and vaginal dryness (64%; p = 0.03) compared with placebo group. POST women primarily showed an increased in level of sexual desire, with 51% showing improvement, compared with only 8% in the placebo group (p = 0.008). Nutritional intervention plays an important role in women's sexual health, but issues and areas of greatest improvement differ among women of different menopausal states. The largest number of attribute improvements were seen in PRE and PERI women, although attribute types vary among these groups. Level of desire was shown to increase significantly in POST women. Since ArginMax for women has been shown to exhibit no estrogen activity, it may be desirable alternative to hormone therapy for sexual concerns. DOI: 10.1080/00926230600834901 PMID: 16959660 [Indexed for MEDLINE]

A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function.

3. J Sex Marital Ther. 2001 Oct-Dec;27(5):541-9. doi: 10.1080/713846828. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. Ito TY(1), Trant AS, Polan ML. Author information: (1)University of Hawaii, School of Medicine, Honolulu, Hawaii, USA. This study was open to women over the age of 21 years with an interest in improving their sexual function. Of the 77 participants, 34 received ArginMax and 43 received a placebo. ArginMax for Women is a proprietary nutritional supplement consisting of extracts of ginseng, ginkgo, and damiana, L-arginine, multivitamins, and minerals. After 4 weeks, 73.5% of the ArginMax group improved in satisfaction with their overall sex life, compared with 37.2% of the placebo group (p < 0.01). Notable improvements were also observed in sexual desire, reduction of vaginal dryness, frequency of sexual intercourse and orgasm, and clitoral sensation. No significant side effects were noted. DOI: 10.1080/713846828 PMID: 11554217 [Indexed for MEDLINE]

Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

4. Biomed Pharmacother. 2022 Feb;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 7. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Scuteri D(1), Rombolà L(2), Hamamura K(3), Sakurada T(4), Watanabe C(5), Sakurada S(6), Guida F(7), Boccella S(8), Maione S(9), Gallo Afflitto G(10), Nucci C(11), Tonin P(12), Bagetta G(13), Corasaniti MT(14). Author information: (1)Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy. Electronic address: damiana.scuteri@unical.it. (2)Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. Electronic address: laura.rombola@unical.it. (3)Department of Pharmacology, Daiichi University of Pharmacy, 815-8511 Fukuoka, Japan. Electronic address: k-hamamura@daiichi-cps.ac.jp. (4)Department of Pharmacology, Daiichi University of Pharmacy, 815-8511 Fukuoka, Japan. Electronic address: tsukasa@daiichi-cps.ac.jp. (5)Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan. Electronic address: chizu@tohoku-mpu.ac.jp. (6)Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan. Electronic address: s-sakura@tohoku-mpu.ac.jp. (7)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. Electronic address: franc.guida@gmail.com. (8)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. Electronic address: boccellaserena@gmail.com. (9)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy; Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, Pozzuoli, Italy; IRCSS, Neuromed, Pozzilli, Italy. Electronic address: sabatino.maione@unicampania.it. (10)Ophthalmology Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. Electronic address: gabrielegalloafflitto@gmail.com. (11)Ophthalmology Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. Electronic address: nucci@med.uniroma2.it. (12)Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy. Electronic address: p.tonin@isakr.it. (13)Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. (14)Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy. Electronic address: mtcorasa@unicz.it. BACKGROUND: Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment. METHODS: Literature search includes the most relevant repositories for medical scientific literature from inception until November, 24 2021. Data collection and selection of retrieved records adhere to PRISMA criteria. RESULTS: In agreement with a priori established protocol the search retrieved 2471 records leaving 479 results after duplicates removal. Eleven records result from title and abstract screening to meet the inclusion criteria; only 4 results are eligible for inclusion in the qualitative synthesis impeding meta-analysis. The qualitative analysis highlights the antinociceptive and anti-inflammatory efficacy of Δ8-tetrahydrocannabinol, cannabidiol and its derivative HU-308 and of new racemic CB1 allosteric ligand GAT211 and its enantiomers GAT228 and GAT229. Moreover, CB2R agonists RO6871304 and RO6871085 and CB2R ligand HU910 provide evidence of anti-inflammatory efficacy. CB2 agonist HU308 reduces of 241% uveitis-induced leukocyte adhesion and changes lipidome profile. Methodological and design issues raise concern of risk of bias and the amount of studies is too small for generalization. Furthermore, the ocular pain model used can resemble only inflammatory but not neuropathic pain. CONCLUSIONS: The role of the endocannabinoid system in ocular pain is underinvestigated, since only two studies assessing the effects of cannabinoid receptors modulators on pain behavior and other two on pain-related inflammatory processes are found. Preclinical studies investigating the efficacy of cannabinoids in ocular inflammatory and neuropathic pain models are needed to pave the way for clinical translation. Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved. DOI: 10.1016/j.biopha.2021.112505 PMID: 34891121 [Indexed for MEDLINE]

NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol.

5. Biomed Pharmacother. 2022 Sep;153:113488. doi: 10.1016/j.biopha.2022.113488. Epub 2022 Aug 4. NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol. Scuteri D(1), Guida F(2), Boccella S(3), Luongo L(4), Maione S(5), Tonin P(6), Nicotera P(7), Bagetta G(8), Corasaniti MT(9). Author information: (1)Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy. Electronic address: damiana.scuteri@unical.it. (2)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. Electronic address: franc.guida@gmail.com. (3)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. Electronic address: boccellaserena@gmail.com. (4)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. Electronic address: livio.luongo@gmail.com. (5)Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy; Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, 80078 Pozzuoli, Italy; IRCSS, Neuromed, 86077 Pozzilli, Italy. Electronic address: sabatino.maione@unicampania.it. (6)Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy. Electronic address: patonin18@gmail.com. (7)German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Electronic address: pierluigi.nicotera@dzne.de. (8)Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. Electronic address: giacinto.bagetta@unical.it. (9)Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy. Electronic address: mtcorasa@unicz.it. Up to 80 % nursing home residents with dementia experiences chronic pain. Contextually, 97 % presents fluctuant neuropsychiatric symptoms (NPS). Among the most challenging is agitation, connected with undertreated pain and managed through neuroleptics doubling death risk. Evidence is accumulating in favor of the involvement of the endocannabinoid system in nociception and NPS. This double-blind, placebo-controlled, randomized trial (NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia [NACTOPAISD]) aims at investigating efficacy and safety of oral spray nabiximols, containing Δ9-tetrahydrocannabinol and cannabidiol (Sativex®), for pain and agitation treatment in severe dementia patients (Mini-Mental State Examination ≤ 12) over 65. The coprimary endpoints are efficacy on pain and agitation, assessed through the recently validated Italian Mobilization-Observation-Behavior-Intensity-Dementia and the Cohen-Mansfield Agitation Inventory. The secondary endpoint is the evaluation of efficacy duration after wash-out and the assessment of quality of life through the DEMQOL. Any adverse events will be reported. The results undergo statistical analysis plan. NACTOPAISD might provide rationale for a translational safer pain and agitation treatment in severe dementia. It is approved by Calabria Region Ethics Committee and follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and the Consolidated Standards of Reporting Trials (CONSORT) statements. Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. DOI: 10.1016/j.biopha.2022.113488 PMID: 36076584 [Indexed for MEDLINE] Conflict of interest statement: Conflicts of Interest The authors declare no conflict of interest.

Acute effects of a herb extract formulation and inulin fibre on appetite, energy intake and food choice.

6. Appetite. 2013 Mar;62:84-90. doi: 10.1016/j.appet.2012.11.018. Epub 2012 Dec 1. Acute effects of a herb extract formulation and inulin fibre on appetite, energy intake and food choice. Harrold JA(1), Hughes GM, O'Shiel K, Quinn E, Boyland EJ, Williams NJ, Halford JC. Author information: (1)Kissileff Laboratory for the Study of Human Ingestive Behaviour, Department of Experimental Psychology, Institute of Psychology, Health and Society, University of Liverpool, Eleanor Rathbone Building, Bedford Street South, Liverpool L69 7ZA, UK. harrold@liverpool.ac.uk The impact of two commercially available products, a patented herb extract Yerbe Maté, Guarana and Damiana (YGD) formulation and an inulin-based soluble fermentable fibre (SFF), alone or in combination, on appetite and food intake were studied for the first time in a double blind, placebo-controlled, cross-over design. 58 normal to slightly overweight women consumed a fixed-load breakfast followed 4h later by an ad libitum lunch. They were administered YGD (3 tablets) and SFF (5g in 100ml water), YGD and water (100ml), SFF and placebo (3 tablets) or water and placebo 15min before meals. Appetite was assessed using visual analogue scales, and energy intake was measured at lunch. Significant reductions in food intake and energy intake were observed when YGD was present (59.5g, 16.3%; 112.4kcal, 17.3%) and when SFF was present (31.9g, 9.1%; 80kcal, 11.7%) compared with conditions were products were absent. The lowest intake (gram and kcal) was in the YGD+SFF condition. Significant reductions in AUC hunger and AUC desire to eat were also observed after YGD+SFF combination. The data demonstrate that YGD produces a robust short-term effect on caloric intake, an effect augmented by SFF. Caloric compensation for SFF indicates independent effects on appetite regulation. Copyright © 2012 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.appet.2012.11.018 PMID: 23207186 [Indexed for MEDLINE]

Effectiveness of a herbal formula in women with menopausal syndrome.

7. Forsch Komplementmed. 2011;18(5):264-8. doi: 10.1159/000333430. Epub 2011 Oct 10. Effectiveness of a herbal formula in women with menopausal syndrome. Yakoot M(1), Salem A, Omar AM. Author information: (1)Green Clinics, Alexandria, Egypt. Yakoot@yahoo.com BACKGROUND: Lady 4 is a combination of 4 natural components (evening primrose oil, damiana, ginseng, royal jelly) with a known history of traditional use for menopausal symptoms. OBJECTIVE: To study efficacy and safety of Lady 4 in women suffering from menopausal syndrome. METHODS: 120 women with menopausal symptoms were randomised into an experimental group treated with 2 capsules of Lady 4 daily and a control group treated with placebo. The outcome was measured by the Menopause Rating Scale II (MRS-II). RESULTS: There was a statistically significant improvement in the MRS-II score in both groups after 2 and 4 weeks of treatment, but the improvement was significantly better in the Lady 4 group (p < 0.001). 86.7% in the Lady 4 group and 56.7% in the placebo group rated the therapy success as 'much improved' or 'very much improved'. CONCLUSION: Lady 4 may be beneficial in the treatment of menopausal syndrome and can be used as a safe natural promoter of health and well-being in women during the menopausal transition. Copyright © 2011 S. Karger AG, Basel. DOI: 10.1159/000333430 PMID: 22105039 [Indexed for MEDLINE]

Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients.

8. J Hum Nutr Diet. 2001 Jun;14(3):243-50. doi: 10.1046/j.1365-277x.2001.00290.x. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. Andersen T(1), Fogh J. Author information: (1)Department of Ultrasound, Medical Center Charlottenlund, Trunnevangen 4A, DK 2920, Charlottenlund, Denmark. BACKGROUND: Obesity and overweight may soon affect more than half of the population in some regions of the world and are associated with diabetes, hypertension and other diseases that cause morbidity, mortality and high health-care expenditure. No one approach, whether dietetic management, medication, or commercial weight loss programme, can alone solve the problem--all potential treatments need to be investigated and exploited. Among the herbal preparations known to non-western cultures are materials which may have applications in modulating physiological processes which influence gut motility, food intake and energy balance. One such mixed herbal preparation is 'YGD' containing Yerbe Maté (leaves of Ilex paraguayenis), Guarana (seeds of Paullinia cupana) and Damiana (leaves of Turnera diffusa var. aphrodisiaca). AIMS: This study had two distinct aims: to determine the effect of a herbal preparation 'YGD' containing Yerbe Maté, Guarana and Damiana on gastric emptying; to determine the effect of the same preparation on weight loss over 10 days and 45 days and weight maintenance over 12 months. METHODS: Gastric emptying was observed using ultrasound scanning in seven healthy volunteers following YGD and placebo capsules taken with 420 mL apple juice. Body weight was observed before and after 10 days of treatment with three YGD capsules or three placebo capsules before each meal for 10 days in 44 healthy overweight patients attending a primary health care centre. Forty-seven healthy overweight patients entered a double-blind placebo-controlled parallel trial of three capsules of YGD capsules before each main meal for 45 days compared with three placebo capsules on body weight. Body weight was monitored in 22 patients who continued active (YGD capsules) treatment for 12 months. RESULTS: The herb preparation YGD was followed by a prolonged gastric emptying time of 58 +/- 15 min compared to 38 +/- 7.6 min after placebo (P = 0.025). Body weight reductions were 0.8 +/- 0.05 kg after YGD capsules compared to 0.3 +/- 0.03 kg after placebo capsules over 10 days, and 5.1 +/- 0.5 kg after PGD capsules compared to 0.3 +/- 0.08 kg after placebo over 45 days. Active treatment with YGD capsules resulted in weight maintenance of the group (73 kg at the beginning and 72.5 kg at the end of 12 months). CONCLUSIONS: The herbal preparation, YGD capsules, significantly delayed gastric emptying, reduced the time to perceived gastric fullness and induced significant weight loss over 45 days in overweight patients treated in a primary health care context. Maintenance treatment given in an uncontrolled context resulted in no further weight loss, nor weight regain in the group as a whole. The herbal preparation is thus shown to be one that significantly modulates gastric emptying. Further clinical studies with dietetic monitoring of energy intake, dietary quality, satiety ratings, body weight and body composition are now indicated, and examination of the active principles contained in the three herbal components may prove rewarding. DOI: 10.1046/j.1365-277x.2001.00290.x PMID: 11424516 [Indexed for MEDLINE]